Skip to content

Combustion Derived Air Pollution and Vascular Function

The Effects of Combustion-Derived Air Pollution on Vascular Vasomotor and Fibrinolytic Function in Healthy Volunteers (Diesel Exposure)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00775099
Enrollment
16
Registered
2008-10-17
Start date
2005-09-30
Completion date
2006-03-31
Last updated
2008-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction

Keywords

Air Pollution, Particles, Particulate Matter, Vascular function, Endothelial function, Thrombosis

Brief summary

Air pollution is a major cause of cardiovascular morbidity and mortality. The components of air pollution responsible and the mechanisms through which they might mediate these harmful effects remain only partially understood. The link between cardiovascular disease and air pollution is strongest for fine particulate matter. Fine particulate matter (PM) is produced from the combustion of fossil fuels with the most significant threat thought to be posed by small particles less than 10µm (PM 10) which can be inhaled into the lungs. We propose to identify the precise component of diesel exhaust that mediates the adverse cardiovascular effects using a carbon particle generator, and a particle concentrator. The aim of this study proposal is to assess the vascular effects of different types and components of air pollution in healthy subjects. We intend to test the hypotheses that: 1. Combustion derived nanoparticulate causes an acute impairment of endothelial vasomotor and fibrinolytic function in healthy volunteers. 2. Exposure to combustion derived air pollution is associated with increased thrombus formation.

Interventions

Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).

Ex-vivo assessment of thrombus formation using Badimon Chamber

Sponsors

National Institute for Public Health and the Environment (RIVM)
CollaboratorOTHER_GOV
University of Edinburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers

Exclusion criteria

* Current smokers * Significant occupational exposure to air pollution * History of lung disease * Women of child-bearing potential * Malignant arrhythmias * Renal or hepatic failure * Significant co-morbidity * Systolic blood pressure \>190 or \<100 mmHg * Previous history of blood dyscrasia * Unable to tolerate the supine position * Lack of informed consent * Blood donation within last 3 months

Design outcomes

Primary

MeasureTime frame
Forearm blood flow measured by forearm venous occlusion plethysmography in response to infused vasodilators6-8 hours after exposure

Secondary

MeasureTime frame
Ex-vivo thrombus formation assessed using the Badimon chamber6 hours after exposure
Arterial stiffness measured by radial artery tonometryBefore and after exposure
Heart rate and heart rate variability measured with 3 lead Holter electrographic monitorsDuring and for 24 hours after exposure
Plasma t-PA and PAI concentrations following infusion of bradykininDuring forearm study
Plasma inflammatory markers IL-6, TNF-alpha, IL-1 and hsCRPBefore and after exposure
Platelet monocyte binding as measured by flow cytometryAfter the exposure
Blood pressureDuring and after exposure and during forearm study

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026